| Filed On | Filing |
|---|---|
| 06 Jul 2026 |
8-K/A: Departure/Election of Directors or Officers; Compensation
1 Private & Confidential July 2026 Albert Manzone Dear Albert, Perrigo Pharma International D.A.C (Perrigo) is pleased to offer you the position of Interim President and Chief Executive Officer. Our employment offer is subject to the ter... |
| 06 Nov 2024 |
8-K/A: Results of Operations and Financial Condition
Company Delivered Solid Third Quarter Financial Results, Including Meaningful Operating Income Growth and Margin Expansion |
| 15 Jul 2022 |
8-K/A: Completion of Acquisition or Disposition of Assets
We have audited the consolidated financial statements of HERA S.A.S. and its subsidiaries (the Company), which comprise the consolidated statement of financial position as of December 31, 2021, and the related consolidated statements of ... |
| 21 Jul 2017 |
8-K/A: Departure/Election of Directors or Officers; Compensation
Confirming our discussion, this letter outlines the new terms associated with your ongoing role as the Acting CFO of Perrigo (the “Company”). These terms have been approved by the Company’s Board of Directors. |
| 30 May 2017 |
8-K/A: Financial Statements and Exhibits
On March 27, 2017, Perrigo Company plc (“Perrigo” or the “Company”) completed the divestiture of its contingent payments from Elan Corporation, plc’s May 2013 sale of the multiple sclerosis drug Tysabri® (natalizumab) to Biogen Idec, Inc... |
| 15 Jun 2015 |
8-K/A: Financial Statements and Exhibits
(Dollar and Euro amounts presented in millions, except per share amounts) |
| 18 Feb 2014 |
8-K/A: Financial Statements and Exhibits
(Dollar amounts presented in millions, except per share amounts) |
Loading...